1. Scrip
  2. >>R&D

Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds

 
• By Joseph Haas

Just moving into Phase II with a pair of candidates, Pfizer trails smaller rivals in the NASH race, but the deep-pocked firm may have the assets to develop its own proprietary combination therapy for the large-scale unmet medical need.

Morrie Birnbaum of Pfizer
Pfizer Chief Scientific Officer, Internal Medicine, Morris Birnbaum

Pfizer Inc.’s R&D efforts in non-alcoholic steatohepatitis (NASH) have been going on for about six and a half years, but the pharma only presented its first clinical data for a NASH candidate at the 2018 International Liver Conference in April. The company is advancing three clinical candidates for NASH, with a diabetes candidate also possibly offering potential in the unmet medical need, with a focus on reducing fat in the liver and the hope that other aspects of the disease will show benefit as well.

“Because we're operating [the program] out of a metabolic unit and that's our bias as well as our expertise, we...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from R&D

The Expanding MASH Market: How Rezdiffra, Wegovy Might Coexist

 
• By Joseph Haas

FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.

Pipeline Watch: Eight Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Alnylam Pairs Zilebesiran With Diuretics After Phase II Endpoint Miss In Hypertension

 
• By Manas Mishra

Alnylam and Roche refine zilebesiran’s Phase III trial design after a Phase II miss, focusing on patients on diuretics.

AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout

 
• By Andrew McConaghie

There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.

More from Scrip

Sanofi’s Wayrilz Gets Out Of The Blocks With First US Approval For ITP

 
• By Alexandra Shimmings

The FDA go-ahead makes it the first for a BTK inhibitor in immune thrombocytopenia. Sanofi hopes it will mark the start of a number of indications for rilzabrutinib.

Alnylam Pairs Zilebesiran With Diuretics After Phase II Endpoint Miss In Hypertension

 
• By Manas Mishra

Alnylam and Roche refine zilebesiran’s Phase III trial design after a Phase II miss, focusing on patients on diuretics.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Lilly’s orforglipron strong in diabetic obesity; Ascletis confident in oral GLP-1 challenger; myostatin drugs progress for obesity; an interview with OneSource’s CEO; and an analysis of Dupixent’s pipeline-in-a-product success.